Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
X
X
technical note

The State of Cell and Gene Therapy Characterization Survey Report

Characterization assays are part of every drug development and manufacturing process to inform a level of safety and efficacy while meeting regulatory requirements before patient administration. However, the development and production of cell and gene therapies (CGTs) is highly variable and presents unique challenges in characterization. We wanted to understand how current CGT developers are grappling with these new hurdles for this newer class of drugs. This included understanding their current workflows, focus areas of therapeutic development, what attributes they measure, how it is measured, and their satisfaction with their current tools.

Mission Bio developed a survey targeting CGT developers and consisted of questions around their current drug programs. The survey specifically focused on their analytical characterization strategies, motivations, and satisfaction level. Highlights include:

  • 40% admit their analytical characterization assays are not sufficient for determining CQAs
  • 56% feel dissatisfied with their characterization approach
  • 81% agree better characterization would reduce risk of holds

Download The cell and gene therapy characterization survey report to learn more.



technical note
Beyond basic characterization: the synergistic power of Tapestri and patient-derived xenografts to accelerate drug discovery
technical note
High-throughput assessment of genome edited cells with Tapestri antibody hashing
technical note
Unprecedented Resolution of Genome Editing Outcomes with Single-cell Analysis
technical note
Single-Cell Measurable Residual Disease (scMRD) Characterization in AML at Unparalleled Resolution
REQUEST QUOTE